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ABSTRACT 
Treatment compliance refers to performing behaviours which follow a 
course of treatment that has been agreed upon by the patient and the 
health care professional. Noncompliance can result in prolongatiorr of 
current health problems, may lead to more extensive treatments, may 
compromise the effectiveness of treatment and may increase the chance 
of recurrence. The present pilot study, carried out at the Thunder Bay 
Regional Cancer Centre, assessed the compliance of 20 female breast 
cancer patients taking Tamoxifen, an oral medication considered to have 
prophylactic benefits. Measures were taken on desirability of control 
(Burger & Cooper, 1979), health locus of control (Wallston, Wallston & 
Devellis, 1978), mood states (the Profile of Mood States, Celia et al., 
1987), quality of life (Functional Living Index - Cancer, Schipper et al., 
1984), and the patients' perceptions of the Cancer Centre, their 
relationship with their oncologist, and their own likely rate of compliance. 
Further, half of the subjects were asked to complete a daily diary of their 
medication taking. Each patients' physician was asked to provide 
information on diagnosis, present status, physical functioning rating and 
likely compliance rate. Subjects were seen four times over a six-week 
period. At these meetings, the investigator counted the number of pills 
(Tamoxifen) remaining in the bottje and asked the subject to complete 
the quality of life measure. Subjects were not told this was a study of 
compliance. 
It was hypothesized that: 
1. patients scoring lower on the quality of life measure would be more 
likely to be compliant than those whose quality of life was high. 
2. patients who displayed an internal locus of control, who scored high 
on desirability of control, and whose relationship with their oncologist 
allowed for this internal/high desire control would be more compliant 
than similar patients whose relationship did not allow for this control. 
3. patients showing signs of mood disturbance would be less compliant 
to the medication regimen. 
4. patients regarding the Centre highly would be more compliant. 
5. patients on the regimen for a longer period of time would be less 
compliant than those just beginning the regimen. 
6. patients' predictions about their own rate of compliance would 
accurately reflect actual compliance, while oncologists' predictions would 
not be accurate and would overestimate actual compliance rates. 
7. patients who kept a daily medication diary would be more compliant 
than those not using a diary. 
The hypotheses were not supported by the data with the exception that 
oncologists' predictions of compliance were not related to actual 
compliance. However, age was significantly related to compliance in that 
older women were more likely to be compliant to the medication 
regimen. Also, it appears that oncologists base their estimations of 
compliance on the length of time which has elapsed since the patient first 
began treatment - a factor showing no relationship to actual compliance 
rate. Several tentative, albeit statistically nonsignificant, relationships 
provide compelling suggestions for future research. Also, implications for 
the care of cancer patients are discussed. 
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2 
Medication Compliance Among 
Breast Cancer Patients 
On Long-Term Adjuvant Chemotherapy 
With our increasing medical knowledge and pharmaceutical 
advances, medication regimens are becoming a part of life for many 
individuals. Compliance to these regimens may be the factor which turns 
the tide away from illness and toward health, with the added benefit of 
saving health care dollars. If we are able to identify predictors of 
noncompliance, we will be able to intervene and deal with the problem 
before it adversely affects the patient. This Is as true In the care of 
people with cancer as it is In other types of illness; cancer now being a 
chronic illness and not necessarily the "death sentence" it once was. 
Interest in the care of future cancer patients provides even more 
incentive for maximizing compliance. Many cancer patients participate in 
clinical trials designed to determine the best treatment for a particular 
disease. Noncompliance could have a serious effect on the 
interpretation of the results of that research. Given and Given (1989) 
state that "the results of well designed randomized clinical trials for 
therapeutic approaches ... may be In question without knowledge about 
patients’ compliance levels with the clinical protocol" (p. 98). Identifying 
3 
the incidence of noncompliance in this population (I.e. cancer patients) 
and some of the factors associated with it would allow us to predict 
which patients are more likely to be noncompliant and the extent to 
which it may be a problem to consider in specific clinical trials. 
In general, compliance is a term used to refer to health behaviour, 
on the part of a patient, that follows medical advice. It can be a 
controversial term to use since, to many people, it suggests passive 
obedience. For this reason, other terms with less negative connotations 
have been suggested, such as adherence, cooperation, collaboration, 
and therapeutic alliance (Feist & Brannon, 1988; Barofsky, 1978). 
However, compliance and adherence are still the most widely recognized 
and accepted labels to describe a person’s willingness to follow 
recommended health practices, and will be used Interchangeably here. 
Although the specific and operational definition of compliance and 
noncompliance varies across studies, for the purposes of this work 
noncompliance is considered to be failing to adhere to a course of 
treatment which has been negotiated by the patient and the health care 
professional. In this way, modifying the treatment in consultation with the 
physician would not be considered noncompliance, but rather a 
renegotiation of a contract. 
In the days prior to the Renaissance, compliance was not an issue 
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because treatments such as bloodletting, leeching, and trephining were 
administered (often by force), rather than being prescribed (Davidson, 
1982). Today however, we recognize the right of the individual to know 
the treatment options available to him/her and to make conscious, 
informed choices involving this treatment. The patient is in a unique 
situation with health care professionals in that he/she must trust but also 
doubt and must accept but also question (Fitzpatrick, Hinton, Newman, 
Scambler, & Thompson, 1984). This raises the possibility that patients 
will not comply with a recommended treatment regimen and, given that 
the success of any intervention depends upon the recipient’s willingness 
and ability to comply or adhere to the recommended course of action, 
noncompliance can be a very serious problem. 
Noncompliance to prescribed medical treatments can result in 
more serious Illness and/or the prolongation of current health problems 
and thus. In the need for more extensive treatment (Gatchel, Baum & 
Krantz, 1989; Food and Drug Administration, 1980). Not complying often 
necessitates more appointments and increases the likelihood of long- 
term terminal care. In addition, if it is not recognized as noncompliance 
by the physician, it can even result in a more powerful, different, and/or 
perhaps even Inappropriate, treatment being prescribed. Masur (1981) 
reports the case of a 25 year old male being followed for essential 
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hypertension who was prescribed antihypertensive agents. Eight weeks 
after the start of therapy, the patient’s blood pressure was still well above 
normal and the physician prescribed more powerful drugs, not knowing 
that the reason for the patient’s lack of improvement was that the patient 
did not comply with the regimen. 
Noncompliance not only jeopardizes the rehabilitation and 
recovery of patients, but results in a heavy burden to the tax-payer. The 
American Food and Drug Administration (1980) has estimated that 
nonadherence costs $400 to $800 million dollars annually. 
Types of Compliance 
Perhaps the most basic form of noncompliance is not appearing 
for a scheduled appointment with a health care provider. It has been 
estimated that 25 - 50 % of persons fail to appear for a scheduled 
appointment (Dunbar & Stunkard, 1979). Sackett and Snow (1979) 
reported that compliance Is higher when patients initiate the contact (at 
an overall compliance rate of 75%) than when the physician initiates the 
contact (at an overall compliance rate of 50%). 
Noncompliance Is also manifested when medication is prescribed. 
Patients may simply fail to fill the prescription, they may fill the 
prescription and then not take the medication, they may take too little or 
too much of it, they may not follow the frequency or dose instructions, or 
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they may stop taking the medication early (Buckaiew & Sailis, 1986; 
Dunbar & Stunkard, 1979). It is this form of compliance which has 
received the most research, since noncompliance with a medical regimen 
can have an immediate, and sometimes dramatic effect on one’s life. In 
general, compliance to medical treatment Is estimated at approximately 
50% (Stone, 1979). 
Thirdly, and it would appear that this happens quite often, patients 
may fail to make recommended life style changes. Dunbar and Stunkard 
(1979) estimate that, in general, 20 - 80% of participants drop out of 
lifestyle change programmes. Sackett and Snow (1979) report that 
noncompliance to dietary regimens approaches 70%; and Dishman 
(1982) estimates that 50% of participants In exercise programmes drop 
out during the first six months. 
Factors Affecting Compliance 
Compliance estimates range considerably, depending upon the 
nature of the physical illness, its threat to life, the adverse nature of the 
interventions, the possible loss of self-esteem due to being ill and 
perhaps not being able to do the things you once did so easily, and, in 
some jurisdictions, the financial burden to the individual undergoing 
treatment. It can also vary depending on how one defines compliance 
(e.g. as keeping appointments, taking all prescribed medication, etc.) 
7 
and on who judges whether a particular act or omission is to be 
considered compliance or noncompliance. For example, a carefully 
thought out decision on the part of the patient not to undergo certain 
procedures may be considered noncompliance by a physician while 
others (including the patient) view it as simply one of the patient’s basic 
rights. Falvo (1985) stressed that when people are faced with illness, 
they may experience fear, anxiety and other reactions that will affect their 
behaviour and "what the health professional may at times perceive as 
noncompliance may actually be that patient’s attempt to gain some 
control over his or her own destiny" (p. xili). Obviously, compliance is a 
very complex issue Involving several factors. 
The many factors possibly associated with compliance can be 
divided into three general categories. These categories include patients’ 
personal characteristics, the nature of the physician-patient relationship 
and illness characteristics. 
Patients’ Personal Characteristics 
Studies have attempted to find personal characteristics which may 
be related to compliance. Characteristics such as age, sex, race, 
religion, educational level, and social class do not appear to reliably 
predict compliance when considered in Isolation (Davidson, 1982). 
However, considering four or more characteristics together can give an 
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indication of the probability of compliance (Masur, 1981). 
A factor commonly Identified with the patient’s ability to comply 
with a prescribed regimen is remembering and understanding the 
physician’s advice. Ley (1979) found that one can expect patients to 
remember about two-thirds of the instructions they are given, if they are 
asked immediately following the office visit. It appears that the more 
information the patient is given, the more he/she forgets (Ley, 1979). 
Dunbar (1980) reports that presenting details of the regimen both in 
writing and verbally; tailoring the instructions to the patient; emphasizing 
the ’how to’ component of the regimen rather than the ’why’; and 
assessing the patient’s comprehension and skill by asking him/her to 
describe what he/she Is going to do when he/she gets home will all help 
the patient to understand and remember what he/she Is to do. 
Cultural beliefs and attitudes are other personal characteristics that 
relate to compliance. People living within a culture that does not have 
faith in modern medical procedures are unlikely to comply with medical 
recommendations (Nyazema, 1984). Further, it appears that patients are 
more likely to comply with such recommendations if their physician 
demonstrates some understanding and respect for their cultural practices 
and beliefs (Ruiz & Ruiz, 1983). 
Another personal characteristic that seems to be related to 
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compliance is social support. People who have close interpersonal 
relationships are more likely to follow medical advice than those whose 
lives are isolated from others. Their family members and friends can 
encourage or remind them to comply with the therapeutic regimen and 
can even give them added reason to follow the regimen and become well 
again (e.g. when a mother reports fighting illness because her child 
needs her). Sherwood (1983) found that compliance by haemodialysis 
patients Increased when family members were Involved and showed an 
understanding of the disease, the medication regimen, and the emotional 
effects of illness. Interestingly, Sherwood (1983) also found that there is 
an ideal level of family Involvement midway between family members 
being emotionally distant and being emotionally overinvolved. 
Quality of Life is another patient variable which may impact on 
compliance. Quality of Life measures, particularly in cancer care, assess 
such things as freedom from pain, sociability, “impact" of the illness and 
satisfaction. It can be said that quality of life "reflects a composite of 
factors that individuals view as important to the reality of functional living" 
(Schipper, Clinch, McMurray & Levitt, 1984, p. 473). Those patients 
scoring lower on such measures are reporting more illness symptoms 
and more general dysfunction than their counterparts with higher quality 
of life scores. While research evaluating a possible relationship between 
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quality of life and compliance has not been done, common sense 
suggests that those people who are not experiencing active illness 
symptoms may be less likely to comply with medication regimens. Many 
of us have had the experience of strictly following an antibiotic regimen 
while feeling ill, but then forgetting to take the medication more and more 
after beginning to recover. Perhaps the same thing happens with other 
medication regimens. 
Personality traits are another aspect of patient characteristics 
which have been studied. For a time, there was a search for the 
’compliant personality’ (Bloom, 1988). Research In this area has been 
equivocal. Some research has reported a link between noncompliance 
and personality factors such as authoritarianism, neuroticism, and 
impulsivity (Davis, 1968; Jacobs, 1972; Fitzpatrick et al., 1984) while 
other researchers state that strong evidence to back up the claim of a 
relationship between personality and compliance does not exist 
(DiMatteo & DiNIcola, 1982; Feist & Brannon, 1988). 
One particular personal characteristic which has received a lot of 
attention in the area of compliance is locus of control. Locus of control 
is concerned with what we believe determines the events in our lives. It 
may be internal (i.e. we believe events are determined by our own 
behaviour) or external (i.e. we believe events are determined by chance 
11 
or powerful others). Again, the conclusions about the impact of locus of 
control on compliance are varied. DiMatteo and DiNicola (1982) and 
Feist and Brannon (1988) state that the two are not related, while other 
researchers provide evidence that they are. 
Blotcky, Cohen, Conatser and Klopovich (1985) compared 
adolescents who refused cancer treatment with consenting adolescents. 
The refusers tended to have a more external locus of control than the 
adolescents who consented to treatment. In other words, they felt their 
health was not something over which they had control. In a similar 
study, Jamison, Lewis and Burish (1986) found that adolescents with an 
external locus of control tended not to cooperate or comply with 
treatment. 
Poll and Kaplan De-Nour (1980) studied locus of control in respect 
to adjustment to chronic haemodialysis and compliance with the required 
diet for these patients. They found that those with an internal locus of 
control tended to adjust and adapt better than those with an external 
locus of control. Further, 'internals’ complied with the diet more than 
'externals’. This issue then does seem to have some influence on 
compliance and so study evaluating the link between the two should 
continue. 
How much control one desires is another issue to consider. 
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Perhaps some patients want to be actively involved in their treatment and 
when this involvement is not allowed, they fail to comply in an attempt to 
have control in some manner (Falvo, 1985). This issue has not been 
examined in relation to compliance. However, Blanchard, Labrecque, 
Ruckdeschel and Blanchard (1988) reported that 69% of patients prefer 
to participate in therapeutic decisions-making (i.e. they desire control). 
Blanchard et al. (1988) also report that 25% of patients prefer an 
authoritarian relationship with physicians in which the physician takes 
charge and tells the patient what to do, rather than a participatory or 
negotiative relationship. Thus, there is obviously a difference in how 
much people wish to be directly involved in their health care and this 
difference may Impact on compliance. Desirability of control then 
appears to be closely linked to patient-physician relationship - the next 
set of factors to be discussed. 
Patient-Physician Relationship 
The lack of a definitive link between compliance and personal 
characteristics has led some researchers to believe that perhaps 
compliance should be thought of as being a comment on a relationship 
(e.g. physician-patient, therapist-client, clinic-public) rather than a 
description of a person. Practitioner-patient interaction variables do 
appear to play a role In patient compliance. Patients who experience a 
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delay in getting an appointment with a physician and those who wait in a 
waiting room for an hour or more are more likely to be noncompliant 
(Feist & Brannon, 1988). 
On the other hand, patients tend to be more compliant if they view 
their physician as friendly, nonauthoritarian, interested in the patient’s 
welfare, and if they are satisfied with the relationship they have with their 
physicians (Gastorf & Galanos, 1983; Fitzpatrick et al., 1984). In 
addition, Gilbar (1989) reported that the less confidence a patient has In 
her physician, the more likely that patient is to refuse chemotherapy. 
Further, compliance has been found to decrease when physicians 
are seen as authoritarian or directive (Gastorf & Galanos, 1983). Turk, 
Salovey and Lift (1986) report that fostering a sense of active 
participation is critical to forming a working relationship between patient 
and physician. They go on to suggest that this lays the groundwork for 
compliance. However, Blanchard et al.’s (1988) work reveals that not 
everyone wants this type of relationship. What happens to compliance 
when patients do not get the type of relationship they want? 
KIncey, Bradshaw and Ley (1975) report that patients who feel 
disappointed or dissatisfied when leaving a clinic are more likely not to 
follow advice or take prescriptions as required. In describing situations in 
which the patient was dissatisfied with the communication with the 
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physician, Fitzpatrick et al. (1984) concluded that the physician had 
perceived their responsibility as being the treatment of the disease rather 
than the treatment of the person and “in some sense, they must have felt 
their responsibilities at an end when they had solved the diagnostic 
puzzle and announced their solution. However, for the patient, treatment 
had yet to begin and until they could see the connection between the 
worries which brought them to the doctor and the advice given, they 
were unlikely to follow instructions" (p. 96). This points out the need for 
more study on the impact of the patient-physician relationship on 
compliance. 
Illness Characteristics 
Disease characteristics are a third group of factors which can have 
an impact on compliance. Severity of the illness is often thought to be 
important, and common sense suggests that people with severe, 
perhaps life-threatening illnesses would be more likely to be compliant. 
This however is not necessarily the case. In fact, it appears that a 
physician’s objective opinion of the severity of a disease is not related to 
compliance, but the patient’s perception of disease severity Js important 
(Hulka, 1979; Becker & Maiman, 1980). Patients who perceive 
themselves as susceptible to an illness seem to be more compliant. 
Severity of side effects is another illness characteristic which is 
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widely assumed to be related to compliance. It would be easy to 
assume that compliance to a non-toxic drug would be higher than 
compliance to a drug with many unpleasant side effects. This issue 
could be especially important in considering compliance in cancer 
patients because the treatments often have such distressing and long- 
lasting side effects (e.g. hair loss). Lee (1983) and Smith, Rosen, 
Trueworthy and Lowman (1979) do report that unpleasant side effects of 
drugs was the most compelling reason for noncompliance in cancer 
patients. On the other hand, Masur (1981) reports that unpleasant side 
effects are not a major reason for noncompliance to medical treatment. 
Indeed, some people may even interpret toxicity of drugs as evidence 
that the treatment is working and therefore may welcome the side effects. 
Side effects and compliance may still be related, but more research is 
needed to determine how important they figure in a patient’s 
noncompliance. 
Research has revealed that the longer a person must remain in 
treatment, the more likely it is that the person will be noncompliant 
(Haynes, 1976). Berger, Braverman, Sohn and Morrow (1988) found that 
cancer patients exhibited 100% compliance to therapy at two months and 
that this reduced to 82% compliance at six months and 75% compliance 
at one year. Closely related to the issue of duration of treatment is the 
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complexity of the treatment. It appears that the number of daily doses 
required is not definitely related to compliance but if patients are required 
to take a variety of medications, noncompliance will increase as variety of 
medications increases (Hulka, Cassel, Kupper & Burdette, 1976). 
Measuring Compliance 
Compliance can be measured in several ways. The most obvious 
of these is patient self-report. If patients are reporting past behaviour, 
this report may not be accurate because most patients wish to be 
thought of positively and can not be expected to willingly portray 
themselves negatively by admitting to noncompliance (Sheiner et al., 
1974). Asking questions in such a manner as to anticipate and be 
permissive of reports of failure to comply may offset this trend somewhat 
(Sackett & Haynes, 1976). It appears however that patients will be 
truthful and quite accurate if asked to predict to what degree they will 
comply with a given treatment regimen (Dunbar & Stunkard, 1979). 
A second method of assessing compliance is by physicians’ 
estimates. Although this method might appear to be useful, research 
has shown that health care providers tend to overestimate compliance. 
Roth and Caron (1978) assessed compliance in peptic ulcer patients by 
antacid bottle count, patient self-report and physicians’ estimates. They 
found that physicians’ estimates of compliance were significantly better 
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than chance, and were more accurate that the patients’ self-report, but 
were nevertheless quite low in accuracy. Further, physicians’ accuracy 
did not improve as they gained familiarity with the patient. 
Another method that has been used to assess compliance is 
clinical outcome - if the patient’s condition improves, it can be assumed 
that he/she was compliant. There are serious problems associated with 
using this method. The outcome of a treatment regimen is dependent on 
many factors, only one of which is compliance. The medication must be 
the appropriate one and must be prescribed at an adequate dosage level 
and it must be a treatment to which the patient is biologically responsive. 
If the prescribed treatment is relatively ineffective, compliance and 
improvement will be unrelated. Further, improvement may occur as a 
result of factors other than medical care and patients may take several 
medications with varying degrees of compliance, making it difficult, if not 
impossible, to determine which medication might have been related to 
the improvement (Bloom, 1988). 
Compliance can also be measured by pill counts or medication 
measurement. This is a commonly used method given that it Is easily, 
quickly and inexpensively carried out. On the one hand, this is effective 
because medication that is still in the bottle has clearly not been taken by 
anyone. However, it can become problematic when the medication Is 
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gone. This medication may or may not have been taken according to 
the prescription (e.g. in terms of frequency). It may have been discarded 
rather than being taken. It may even have been taken by someone other 
than the person for whom it was intended. These possibilities must all 
be considered. 
Medication monitors are sometimes used to assess compliance. 
These are devices which measure when medications are removed from 
containers. Masur (1981) reported an interesting use of such a device. 
The pills to be taken were packaged In a stack and alongside the stack 
was a strip of radiation sensitive film. On top of the stack was a radiation 
emitting chemical (a small uranium source) and a spring that kept 
pressure on the stack. Removing pills at regular Intervals left a pattern of 
equally dark spots on the film. Forgetting to take a pill for a long period 
of time resulted in a very dark spot on the film. Removing several pills at 
once resulted in an absence of spots. An obvious problem with this 
method is the cost associated with the development and use of such 
monitors. 
A sixth method of measuring compliance is by direct chemical 
analysis of urine or blood serum to detect the presence of the medication 
or a tracer that was added to the medication. These chemical tests are 
the most accurate methods for measuring compliance that are currently 
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available (Bloom, 1988) and yet they are not without problems. They are 
inconvenient and, in the case of blood tests, invasive. Not all 
medications can be traced or tested and some are absorbed by the 
body too quickly, others too slowly. Not all lab procedures are perfectly 
reliable and many are time-consuming and costly. Levels of tracers can 
be influenced by changes in body metabolism, diet or weight and finally, 
many tests can not distinguish between a medication taken regularly and 
one taken irregularly but just before the blood or urine sample is 
collected. 
Compliance and Cancer 
Hoagland, Morrow, Bennett and Carnrike (1983) surveyed 
oncologists about the extent of and reasons for cancer patient 
noncompliance. Ten potential compliance problem areas were Identified 
and the majority of oncologists reported having some problem with nine 
out of ten of these areas. The noncompliance behaviour which was seen 
to be a problem by the greatest number of oncologists was that of the 
cancer patient who accepts treatment and then fails to complete the 
entire protocol. The main reasons given by oncologists for patient 
noncompliance were psychological problems such as denial and fear, 
but treatment side effects were also seen as contributing to 
noncompliance. 
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Authors differ in their estimations of compliance among cancer 
patients and the degree to which they believe compliance is even an 
issue in the treatment of cancer. Gerber and Nehemkis (1986) explain 
that while "noncompliance colors every aspect of dialysis treatment. . . 
the opposite is true of advanced cancer patients in whom the incidence 
of noncompliance to their likewise demanding treatment program is 
negligible" (p.73). Barofsky (1984), in reviewing investigations looking at 
noncompliance among cancer patients, concluded that the relative lack 
of such studies, and the perception that noncompliance is of minimal 
concern among oncologists, is due in part to the fact that most 
treatments are provider rather than self administered. The studies which 
are available however, reveal that cancer patients are noncompliant and 
are, in fact, as noncompliant as patients with other diseases. 
Smith et al. (1979) studied prednisone compliance in children and 
adolescents with cancer during three phases of therapy. Compliance 
was evaluated through random urine i7-ketogenic steroid assay. The 
authors found that 33% of all patients were not complying. Analysis of 
patients by age group revealed that 59% of adolescents were not 
complying with their prednisone therapy. Given the advances which 
have been made in treating childhood cancers, noncompliance In this 
group can have especially tragic consequences, particularly if a child’s 
21 
lifespan is shortened. 
In looking at adults, Wellisch et al. (1983) reported that in their 
study, when asked directly about their compliance, 26% of cancer 
patients indicated they had not adhered to treatment as directed. 
Noncompliance was explained to the patients as "failing to follow and/or 
refusing prescribed treatment routing (e.g. drugs, chemotherapy, etc.)" p. 
12. Details regarding the reasons for noncompliance were not provided. 
In another study, Barofsky and Sugarbaker (1979) approached 
patients to participate in sarcoma clinical trials. Of those who agreed to 
participate, 16.5% were noncompliant in that they did not complete the 
treatment as prescribed. These patients cited the aversive aspects of 
treatment such as amputation and chemotherapy side effects as the 
major reason for noncompliance. 
Similarly, side effects of treatment was given as the reason for 
noncompliance for the majority (71%) of the noncompliers in Wilcox et 
al.’s (1982) study. They defined noncompliance as discontinuing 
adjuvant chemotherapy and reported an overall rate of noncompliance of 
27% among breast cancer patients. 
Treatment-related complications or side effects and 
noncompliance were not correlated in a study conducted by Berger et al. 
(1988). They studied compliance In patients with locally advanced breast 
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cancer. Compliance was defined as completing the chemotherapy 
protocol as prescribed, and treatment took place at a large municipal 
hospital. They found that 25% of the patients were not compliant 
according to this criteria. Duration of treatment and Initial delay in 
seeking treatment were the factors most closely related to 
noncompliance in this study. 
As further evidence of the Important effect of both duration of 
treatment and side effects on compliance, Lee (1983) studied breast 
cancer patients who accepted post mastectomy adjuvant chemotherapy. 
She found that 77% of the patients stayed on the treatment for at least 
six months, and that compliance declined over time, with 50% of patients 
staying on the treatment for 12 months or more. Side effects of 
treatment as well as "personal and psychosocial factors" were given as 
reasons for discontinuing treatment. Examples of personal and 
psychosocial factors were not provided. 
In a very recent article, Lebovits et al. (1990) studied the 
prevalence of noncompliance with self-administered chemotherapy. 
These authors measured compliance via patient report during repeated 
Interviews over a six month period. Dosage noncompliance was defined 
as the patient Ingesting 90% or less of the total prescribed dosage of 
medication. There was also a behavioural definition in which 
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noncompliance was judged to have occurred if the patient, at any one of 
the visits, reported ingesting 90% or less, or 110% or more, of the 
prescribed medication. They found that 43% of patients met these 
criteria for noncomplianoe. Thus, it appears obvious that compliance is a 
very serious concern in treating cancer patients and one which requires 
further research into the best ways to measure it and the best ways to 
maximize it. 
Proposed Research Question 
To summarize, compliance in cancer care is an area which has 
received relatively little study to date. Given the prevalence of cancer 
and the seriousness of this chronic illness, it is imperative that we 
understand the issue and take steps to deal with noncompliance before it 
jeopardizes a patient’s health. 
Many factors have been discussed which may be related to the 
compliance of cancer patients. Obviously, these can not all be 
addressed within the scope of this one pilot study. Thus, certain 
variables have been chosen for examination to provide a starting base 
for the study of these variables In compliance (I.e. desirability of control 
and quality of life) or because results have been somewhat equivocal 
and need to be clarified. Finally, a very simple intervention will be made 
with half the subjects to evaluate Its impact on compliance. 
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This pilot study will look at assessing compliance in breast cancer 
patients receiving the drug Tamoxifen. Compliance will be operationally 
defined according to medication Ingestion. Patients who ingest 90-100% 
of their medication will be judged to be highly compliant. Patients 
ingesting 75-89% of their medication will be considered moderately 
compliant and patients ingesting 60-74% of their medication will be 
considered to be exhibiting low levels of compliance. Patients ingesting 
less than 60% of the medication will be considered noncompliant. It is 
expected that some patients may appear to have taken more than 100% 
of the prescribed medication. In these cases, the observed percentage 
will be converted to a comparable percentage below 100. For example, 
if a subject appeared to have Ingested 125%, the difference from the 
expected percentage is 25; thus, the converted score would be 75%. 
Hypotheses 
It would be infinitely simpler if the variables Involved in this study 
existed in their own right and were not affected by the other variables. 
This however Is completely unrealistic since nothing remains unaffected 
by what happens around It. Davidson (1982) and Masur (1981) report 
that many variables do not affect compliance when considered alone, but 
several considered together can give us an accurate prediction of 
compliance behaviour. Thus, the hypotheses for this study are 
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complicated and involve many interactions. 
1. It is predicted that patients scoring lower on the quality of life 
measure (FLIC) will be more likely to be compliant. Those patients who 
show a higher quality of life will be experiencing fewer ’Illness symptoms’ 
(e.g. nausea) and so will be more likely to forget to take their medication 
or to feel that it is not necessary to strictly adhere to the regimen. 
Further, as a patient’s quality of life changes throughout the course of 
the study, so will their compliance change. In other words, a patient 
scoring high on the FLIC one week, but low on the FLIC at the next 
meeting will exhibit less compliance the first week (when feeling good) 
than when feeling low. 
2. People who display an Internal locus of control, who score high 
on Desirability of Control, and whose primary health care providers have 
negotiated a relationship with them that allows for this control (or active 
participation) on the part of the patient, will be compliant. This 
participatory relationship will be characterized by the physician making an 
effort to include patients In their own treatment decision-making. Also, 
people who attribute control to chance or powerful others (i.e. display an 
external locus of control), who have little desire for control and who are 
In directive relationships with health care providers will be compliant. 
Directive relationships will be characterized by the physician making 
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treatment decisions and telling the patient what must be done. 
On the other hand, patients with a high internal locus of control, 
who desire control but who are in directive relationships with practitioners 
will not be compliant. Similarly, patients displaying a high external locus 
of control, with little desire for control, who are in participatory 
relationships with health care providers will be somewhat overwhelmed 
by having too much control, and thus will be noncompliant. 
3. It is anticipated that patients showing signs of depression (as 
assessed by the POMS) will be less compliant to the medication regimen. 
Included In the symptoms of depression are difficulty concentrating and 
problems with memory. Thus, a patient may not remember whether 
he/she took his/her medication and this may result in the patient being 
labelled noncompliant. 
4. Perception of the centre will affect compliance in that patients 
who regard the centre highly or who do not experience long waits are 
expected to be compliant. Studies have shown that the less faith a 
patient has In modern medical procedures and the longer a patient must 
wait, either for an appointment or in a waiting room, the less compliant 
the patient will be (Nyazema, 1984; Feist & Brannon, 1988). 
5. The longer a patient has been on the medication regimen, the 
less compliant they will be. Berger et al. (1988) found that compliance 
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decreased as the duration of treatment increased. 
6. It is anticipated that patients’ predictions about their rate of 
compliance will accurately reflect the degree of compliance they actually 
do exhibit. This result has been demonstrated in other research (e.g. 
Dunbar & Stunkard, 1979) and it is expected that it will be replicated 
here. Further, it Is predicted that health care providers will not be very 
accurate in their predictions and will probably overestimate the rate of 
compliance exhibited by the patients (Roth & Caron, 1978). 
7. Patients who keep a diary of their medication taking are 
expected to be more compliant than those patients not using a diary. 
The act of self-monitoring one’s behaviour will increase awareness of the 
behaviour and thus will Increase the probability of complying to the 




Subjects were 20 female breast cancer patients taking Tamoxifen, 
a medication which is commonly used for the adjuvant treatment of 
breast cancer. They were recruited on a strictly voluntary basis from the 
Thunder Bay Regional Cancer Centre. Initially, 68 potential subjects were 
contacted by phone, 40 of whom declined, leaving 28 who agreed to 
participate. Of the 40 decliners, 11 (28%) explained they did not have 
transportation readily available to come to the clinic four times. Another 
11 (28%) indicated that they were going on an extended vacation for the 
remainder of the winter. Ten potential subjects (25%) gave no reason for 
non-participation. The remaining 8 women reported that they were too 
busy or too ill to participate. 
Of the 28 women who agreed to participate, four then cancelled. 
Only data from subjects who were in fact prescribed Tamoxifen were 
included In the study. This restriction required the exclusion of two 
subjects who had discontinued Tamoxifen therapy with the knowledge of 
and/or at the suggestion of their attending oncologist. Data from 
another two subjects were excluded from the study because the subjects 
did not bring their medication to any of the meetings. 
The data were collected over a five month period (January 1991 to 
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May 1991) at the Thunder Bay Regional Cancer Centre. 
Materials 
1) The Multidimensional Health Locus of Control (MHLC) Scales 
(see Appendix A) were developed to measure people’s beliefs that their 
health is determined either by their own behaviour (i.e. health control is 
internal e.g. if I take the right actions, I can stay healthy), or by chance 
(e.g. my good health is largely a matter of good fortune), or by powerful 
others (e.g. having regular contact with my physician is the best way for 
me to avoid illness). 
Two equivalent forms, each consisting of 18 items (6 items 
representing each of the three aspects of health control) are available for 
use. Alpha reliabilities ranged from .673 to .767 (Wallston, Wallston & 
DeVellis, 1978). Construct validity of the measure was demonstrated by 
comparing it to scales developed by Levenson (1974) to measure 
generalized locus of control beliefs (Wallston, Wallston & DeVellis, 1978). 
Each MHLC scale correlated significantly with its theoretical counterpart 
among these scales. 
Health status of patients was correlated with MHLC scales to 
provide an indication of predictive validity (Wallston, Wallston & DeVellis, 
1978). These correlations were positive with Internal Health Locus of 
Control (r= .403, £ < .001), negative with Chance Health Locus of 
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Control (r= -.275,^ < .01), and not correlated with Powerful Others 
Health Locus of Control (r= .055). 
2) The Desirability of Control (DC) Scale (see Appendix B) 
consists of 20 items which measure individual differences in the desire 
one has for control over the events in one’s life (Burger & Cooper, 1979). 
This scale has Internal consistency of .80 and test-retest reliability of .75. 
Discriminant validity has been demonstrated by comparing the DC Scale 
with measures of locus of control (Burger & Cooper, 1979). A low 
negative correlation (r= -.19) between these two scales suggests that 
they do indeed measure different constructs. Construct validation 
studies (Langer, 1975) found that subjects scoring high on Desirability of 
Control possessed a belief of personal control over chance outcomes. 
Further, Hiroto and Seligman (1975) found that people who have a high 
desire for control over the events in their lives may respond to 
uncontrollable, unpredictable aversive stimuli with learned helplessness. 
Breast cancer may be considered such an aversive stimuli and so this 
scale was used to assess how much control each subject desired. 
3) The Profile of Mood States (POMS) is an 11 item adjective 
rating form that assesses present mood state (see Appendix C). The 65 
item original scale is often experienced as repetitive and burdensome by 
physically ill patients, so a short form consisting of 11 Items was 
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developed from the Total Mood Disturbance Score (TMDS) provided by 
the POMS (Celia et al., 1987). This form has been used to evaluate 
general distress in cancer patients and it correlates significantly with the 
long form (r= .93,^ < .001). Further, it demonstrates high internal 
consistency (r= .91). To demonstrate the validity of this measure, 
scores of pancreatic cancer patients and gastric cancer patients were 
compared (Celia et al., 1987). It Is known that POMS TMDS scores of 
pancreatic cancer patients are significantly higher than those scores of 
gastric cancer patients. As expected, this same tendency is evidenced in 
scores obtained on this 11 item scale. 
In addition to the 11 adjectives, a visual analog scale developed 
by Dr. Scott Sellick and the author was provided with the POMS. 
Subjects were asked to use this scale to rate their overall enjoyment of 
life during the past week. One end of a 100 mm line was anchored with 
'no enjoyment’ while the other end was anchored with ’excellent’. 
4) The Functional Living Index - Cancer (FLIC) consists of 22 
items which measure the quality of life in cancer patients, including 
physical well being and ability, emotional state, sociability and family 
situation (see Appendix D). Validation of the scale was conducted in 
Canada using 837 patients over a three year period. Construct validity 
was established through factor analyzing the questionnaire (Schipper et 
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al. 1984). Significant correlations between the FLIC and other similar 
measures (e.g. the General Health Questionnaire) provide evidence of 
concurrent validity and suggest that the FLIC may be used as a quality of 
life measure and as a screening tool to identify specific dysfunction 
(Schipper et al., 1984). 
5) The Difficulty Scale is a simple likert-type scale derived by Dr. 
Scott Sellick and the author to evaluate patients’ predictions of potential 
noncompliance. The scale ranged from 0 (no problems) to 3 (many 
problems). Subjects were asked to indicate which number best 
represented the degree of difficulty they expected to encounter In 
following the medication regimen (see Appendix E). 
6) The Patients’ Impressions of TBRCC Scale was constructed by 
Dr. Scott Sellick and the author to evaluate patients’ experiences at and 
satisfaction with the Thunder Bay Regional Cancer Centre (TBRCC) and 
Its physicians and nurses (see Appendix F). It consists of 12 statements 
to which the subject gives a rating of agreement or disagreement on a 
likert-type scale ranging from -3 (strongly disagree) to 3 (strongly agree). 
Included in these 12 statements were two statements which were 
intended to evaluate whether the patient-oncologist relationship was 
primarily participatory (i.e. the physician attempts to Include the patient in 
decision-making [Part B # 2]) or directive (I.e. the physician makes 
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treatment decisions and tells the patient what must be done [Part B # 
6]). A visual analog scale was also provided on which the subject 
indicated overall satisfaction with the TBRCC by placing a mark along a 
100 mm line anchored with extremely dissatisfied at one end and 
extremely satisfied at the other end. 
In addition to the questionnaires and scales, there was a patient 
Information sheet which was completed by the medical oncologist (see 
Appendix G). This sheet was used to obtain information about Diagnosis 
and Present Status (I.e. free of disease, recurrence or metastatic 
disease). Also, the oncologist was asked to estimate each patient’s 
compliance on a 100 mm visual analog scale and to rate the patient 
using the ECOG (Eastern Cooperative Oncology Group) Scale. The 
ECOG Scale is widely used to assess patients’ level of physical 
functioning. The scale ranges from zero to four, with lower numbers 
indicating higher functioning (see Appendix H). 
Procedure 
Potential subjects were Initially contacted by phone call. The study 
was briefly described (see Appendix I) and participation was requested. 
If the subject agreed to participate, an initial meeting with the Investigator 
was arranged and the investigator asked the subject to bring ail 
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prescribed medication to the meeting. Interestingly, few patients 
questioned the logic of this request. Perhaps in their experiences with 
the Cancer Centre, they had been asked to do many things which did 
not seem logical to them and so they were not surprised by the request. 
For those who did question, it was explained that though it seemed 
strange, it was simply a standard procedure the investigator had to 
follow. Patients accepted this explanation. Only one subject disclosed 
that she realized her pills were being counted, and this subject willingly 
and readily brought her medication to the meetings. The investigator 
neither confirmed nor denied her suspicions. 
At the Initial meeting, participants were asked to sign an informed 
consent form (see Appendix J). As can be noted, the subject was not 
told that the study dealt with medication compliance and that their pills 
were being counted. The author recognizes that this raises a serious 
ethical question about the nature of the Informed consent. However, it 
was Important not to influence the results of this study and it was felt that 
subjects might strive to be more compliant than usual if they knew the 
nature of the investigation. Thus the somewhat difficult decision was 
made to keep this information from the subjects. The challenge then 
was to find the best way to provide the subject with enough Information 
to make a decision to participate without revealing the nature of the 
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study. To this end, input was sought from the medical staff at the 
Thunder Bay Regional Cancer Centre, from the Ethics Committee of the 
Thunder Bay Medical Society and from the Ethics Committee of 
Lakehead University. The informed consent form in Appendix J 
represents the results of that quest. 
At the Initial meeting, subjects were also asked to complete the 
Difficulty Scale, the MHLC, the DC, the POMS, the FLIC, and the 
Patients’ Impressions of TBRCC Scale. Prescription medication was 
recorded and Tamoxifen tablets were counted without the subjects’ 
knowledge. 
Subjects were randomly assigned to one of two experimental 
conditions by choosing pieces of paper from a bowl Immediately prior to 
the initial meeting. Half the pieces of paper had a "one" written on them 
while the other half had a "two" written on them. This method assured 
that subjects had an equal chance of being assigned to either group. 
One group (n = 11) was given a diary at the Initial meeting in which 
to keep track of when they had taken any prescription medication and 
how much they had taken (see Appendix K). After a two week period, 
the subjects again met with the experimenter, exchanged the completed 
diary for a new one, completed the FLIC and had their pills counted by 
the investigator surreptitiously. The investigator left the subject to 
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complete the questionnaires, explaining that she had to have the 
secretary record the medication. At that time the Tamoxifen tablets were 
counted using a standard pharmacy tray. The tablets were not directly 
handled, but were poured onto the tray and moved with a pharmacy 
knife. These meetings continued at two week intervals for six weeks (an 
initial meeting and three study meetings with each subject). 
The other group (n = 11) was not asked to complete a medication 
diary, but was still asked to meet with the investigator at two week 
intervals. It was explained to them that their continued adjustment was of 
interest and so they were to meet with the investigator three more times 
to complete more questionnaires (i.e. the FLIC). At these meetings, their 
pills were surreptitiously counted by the investigator. Both groups spent 
the same amount of time with the Investigator and received the same 
amount of investigator attention. 
Following the initial meeting, the patient information sheet was sent 
to the medical oncologist to obtain information on diagnosis, present 
status, ECOG rating and the oncologist’s prediction of the patient’s 




This sample consisted of women who had been diagnosed with 
breast cancer. The ages ranged from 47 - 69 years with a mean age of 
60.55 years (sd = 7.097). Length of time since the patient was first 
prescribed Tamoxifen ranged from 2 - 83 months with a mean of 19.55 
months (sd = 19.734). 
It is interesting to note that 85% (n = 17) of the subjects were 
considered to be free of disease, while 15% (n=3) had a recurrence of 
cancer or metastatic disease. Similarly, patients’ physical functioning 
was high. ECOG ratings showed that 75% (n = 15) were considered fully 
active, 20% (n=4) were restricted only in physically strenuous activity and 
only 5% (n = 1) were unable to carry out any work activities. 
Pill Count 
For each subject, medication compliance was determined by pill 
count. The regimen for each patient required that she take one tablet 
once a day. Tamoxifen tablets were surreptitiously counted by the 
Investigator at each meeting and this amount was converted to a 
percentage. The count taken at the initial meeting served as a baseline. 
At the next meeting, the number of pills missing was divided by the 
number of pills which should have been taken to obtain the percentage 
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ingested. In the event that the percentage exceeded 100%, it was 
converted to below 100% so that the observations used for analysis 
could range from 0 -100% (e.g. if it appeared that a subject ingested 
125% of the medication it was expected she would take according to her 
prescription, this was converted to 75% - the difference between the 
observation and 100 in both of these cases being 25.) If it appeared the 
patient had taken more than 199% of the medication, her compliance at 
that observation was recorded as zero. These percentages were then 
summed and divided by the number of meetings to obtain the average 
compliance rate. 
Only 50% (n=10) of the subjects brought the medication to all 
meetings with the investigator. Another 25% (n=5) forgot to bring the 
medication to the initial meeting but did bring it to the other meetings. In 
these cases, the first time they brought the medication served as the 
baseline and the average pill count was derived from two observations. 
Two other subjects (10%) forgot to bring the medication to one of the 
study meetings. Their average pill count was derived from the two 
counts the investigator was able to obtain. The remaining three subjects 
(15%) forgot the medication twice. For these subjects, the pill data 
consisted of only a baseline and one observation which was used as 
their mean as well. The data for these subjects is obviously not as 
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complete as would be desired but it was not discarded from the analysis 
since failing to bring medication when requested can itself be considered 
an act of noncompliance. These results however point out the limitations 
of pill counting as a measure of compliance, which will be discussed 
more later in this work. 
When subjects did not give the medication to the investigator at 
the beginning of the session, the investigator asked if she had 
remembered to bring it. If she had not, the Investigator simply asked her 
to try to remember to bring it to the next meeting. 
Mean compliance ranged from 85.263% (sd = 30.668) at Time 2 
to 90.32% (sd = 21.106) at Time 1 (see Table 1). Overall, compliance 
was moderate, with a mean of 87.6% (sd = 21.849), and 15 subjects 
were considered to be highly compliant (see Table 2). However, even 
though compliance was generally high, 20% of subjects (n=4) were 
considered to be noncompliant - a relatively large proportion. Further, 
individual subject’s compliance at individual meetings ran the entire 
possible range of 0 -100% On several occasions compliance was 100%, 
but on two occasions, the count (of two different subjects) indicated that 
they had taken 200% and 300% of their expected medication, leaving a 
percentage of 0. 
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Table 1 
Mean Medication Compliance Over Time 
Time Mean Standard Deviation 
1 (n = 19)* 
2 (n = 19)* 










* Instances in which subjects forgot to bring the medication were 
not included in the calculation of the mean and standard deviation. 
Table 2 
Categorized Compliance 
# of Subjects 
High Compliance 15 
(Ingesting 90 - 100%) 
Moderate Compliance 1 
(ingesting 75 - 89%) 
Low Compliance 0 
(ingesting 60 - 74%) 
Noncompliant 4 
(ingesting < 60%) 
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Subject Prediction of Compliance 
Subjects’ evaluations of how much difficulty they would have In 
following the medication regimen ranged from 0 (no problems) to 3 
(some problems). Most subjects anticipated no problems following the 
regimen, with 80% (n = 16) falling into this category. Another 10% (n=2) 
anticipated few problems and 10% (n=2) anticipated some problems. 
Oncologist Prediction of Compliance 
The visual analog scale on which the oncologists gave their 
predictions of patient compliance was broken into seven equal parts for 
ease of analysis. A rating of 1 indicated very low compliance and a 
rating of 7 indicated very high compliance. The mean prediction of 
compliance was 6.0 (sd = 1.338). Several patients (35%, n=7) were 
considered to be very compliant (receiving a rating of 7). Another 50% 
(n = 10) received a rating of 6, while 10% (n=2) received a rating of 5 and 
only 5% (n = 1) were considered noncompliant by the oncologists 
(receiving a rating of 1). Four oncologists were involved in giving 
compliance ratings for patients. The mean prediction given by a 
particular oncologist ranged from 4.8 - 6.5 (see Appendix L). It would 
have been Interesting to analyze for differences according to the 
attending oncologist, however the sample size was too small for such 
analysis. Further, it would be interesting in future to have compliance 
42 
ratings for each patient by more than one oncologist or physician, as a 
check on the reliability of this measure. 
Multidimensional Health Locus of Control 
The Multidimensional Health Locus of Control Scales (MHLC) yield 
scores on three separate scales: Internal Health Locus of Control Scale 
(IHLC), Chance Health Locus of Control Scale (CHLC) and Powerful 
Others Health Locus of Control Scale (PHLC). The normative sample 
consisted of 115 subjects (51% females) approached by a research 
assistant in a metropolitan airport. The mean age of the sample was 42 
years. 
Internal Health Locus of Control. 
Scores on IHLC ranged from 8-28 with a mean of 20.150 
(sd = 4.591). Only three patients scored highest on this measure of 
locus of control, indicating that they believed they had control over their 
own health. Wallston and Wallston (1978) reported that the normative 
sample of 115 people yielded a mean of 25.104 (sd = 4.891). A 
significant difference was found between our sample and the normative 
mean (z = 4.415, p < .01), indicating that the sample subjects did not 
report as strong a belief in personal control over health matters as the 
normative subjects did (see Table 3). 
Table 3 
Comparison of Sample and Normative Data Scores for Variables 
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IHLC = Internal Health Locus of Control 
CHLC = Chance Health Locus of Control 
PHLC = Powerful Others Health Locus of Control 
DC = Desirability of Control 









































Chance Health Locus of Control. 
The CHLC scores ranged from 7-30 with a mean of 18.300 
(sd = 6.650). Only one patient in this sample reported a definite chance 
health locus of control. The normative data reported by Wallston and 
Wallston (1978) yielded a mean of 15.574 (sd = 5.751). A significant 
44 
difference was found between the sample and the normative mean (z = 
-2.067, p < .05), indicating that the sample subjects reported a stronger 
belief that health matters are controlled by chance or luck (see Table 3). 
Powerful Others Health Locus of Control. 
Subjects’ scores on the PH LC scale ranged from 11-36 with a 
mean of 25.300 (sd = 6.35). In this sample, 16 patients reported a belief 
in the control of powerful others over health matters. The normative 
mean, as reported by Wallston and Wallston (1978) was 19.991 (sd = 
5.221). A significant difference was found between the sample and the 
normative mean (z = -4.432, p< .01), indicating that the sample subjects 
did indeed report a stronger belief in the control of powerful others over 
their health (see Table 3). 
Desirability of Control 
Subjects’ scores on the Desirability of Control Scale (DC) ranged 
from 63 - 111 with a mean of 88.150 (sd = 13.739). Scores were divided 
into high Desirability of Control and low Desirability of Control using the 
median (84) as a cutoff point. By this criteria, 11 patients were low on 
Desirability of Control and 9 were high on this measure. The normative 
data of 453 college students reported by Burger and Cooper (1979) 
yielded a mean of 97.3 (sd = 11.64). A z-test indicated that the sample 
subjects desired significantly less control over the events in their lives 
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than did the normative subjects (z = 3.427, p< .01) (see Table 3). 
Profile of Mood States 
The Profile of Mood States (POMS) scores ranged from 0-19 
(n = 19). POMS scale data from one subject was excluded from the 
analysis because of failure to respond to more than 10% of the 
adjectives. The mean score on the POMS was 4.368 (sd = 5.861). 
Celia et al. (1987) reported that the mean of the normative sample of 619 
cancer patients was 10.43 (sd = 8.87). A significant difference was 
found between the sample and the normative mean (z = 2.979, p< .01), 
indicating that the sample subjects experienced less mood disturbance 
than the normative subjects (see Table 3). 
The visual analog scale asking about overall enjoyment of life 
during the past week was broken into 7 equal parts for ease of analysis, 
where 1 represented no enjoyment and 7 represented excellent 
enjoyment. For those who completed this scale, the mean score was 
5.467 (sd = 1.356). Five subjects (25%) did not complete this scale and 
so it was not used for any further analysis. It appeared that some 
subjects had difficulty understanding the concept of the visual analog 
scale for there were several questions about it and with the exception of 
one subject’s POMS, It was the only scale not fully completed by 
subjects. 
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Functional Living Index - Cancer 
Each subject completed the Functional Living Index - Cancer 
(FLIC) four times over the course of the study. Scores on the FLIC 
could range from 22- 154 with higher scores indicating higher quality of 
life. Schipper et al. (1984) reported mean scores ranging from 106 - 143 
with some subjects tested in Winnipeg and others in Edmonton. Mean 
total scores for this sample remained stable over time, ranging from a 
low of 131.950 (sd = 13.165) at Time 1 to a high of 134.650 (sd = 
14.394) at Time 3 (see Table 4). Paired t-tests conducted on the data 
confirmed that none of the differences in mean FLIC scores was 
significant (see Appendix M). The overall mean FLIC score was 133.363 
(sd = 13.274). 
A recent study conducted at the same Cancer Centre yielded an 
overall mean FLIC score of 111.413 (Straw, Sellick & Sellick, 1990). It is 
worth noting that this mean Is lower than that of the present study. The 
sample In the Straw, Sellick and Sellick (1990) study consisted of patients 
who had just begun toxic chemotherapy, while the subjects in the 
present study were generally well. This fact alone could account for the 
difference in mean FLIC scores between these samples. 
Patients* Impressions of TBRCC 
The 100 mm visual analog scale was divided into seven equal 
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Table 4 
Mean FLIC Scores 
















parts for ease of analysis, with lower numbers Indicating low overall 
satisfaction with the cancer centre. Scores ranged from 5 - 7 with a 
mean of 6.850 (sd = .489). It is interesting to note that 90% (n = 18) of 
the subjects reported very high satisfaction with the centre (indicated by 
a rating of 7). 
Ten statements on the Patients’ Impressions Scale dealt with 
impressions of and satisfaction with the centre. Scores could range from 
10-70, with higher scores indicating more positive impressions. For this 
sample, scores ranged from 64 - 70 with a mean of 68.10 (sd = 2.024). 
Eight subjects (40%) received 70 - the highest possible score on this 
scale. 
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The remaining two statements on the Patients’ Impressions Scale 
evaluated the general nature of the physician-patient relationship 
(participatory or directive). There was a full range of responses (i.e. 1-7) 
on both these questions. For the participatory question (i.e. the 
physicians encouraged me to participate in the decision about what 
treatment would be best for me), the mean score was 6.10 (sd = 1.832). 
For the directive question (i.e. the physicians decided what treatment 
would be best for me and expected me to follow their advice), the mean 
score was 5.300 (sd = 2.364). 
These two questions were correlated to determine whether they 
adequately discriminated between these two methods of interacting. The 
results suggested that those who indicated that their patient-physician 
relationship was participatory did not endorse the statement suggesting 
that the physician was directive in his/her dealings with them. However, 
this result did not reach statistical significance (r = -.3232, p = .165). In 
taking a closer look at the data, it was found that only 40% (n = 8) of the 
subjects’ relationships with physicians fit neatly into one type of 
relationship or the other. Six subjects (30%) indicated that they were in a 
participatory relationship with the physicians at the centre (evidenced by 
a high score on the participatory question and a low score on the 
directive question), while two subjects (10%) indicated that they were In a 
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directive relationship with the physicians. The remaining 60% 
(n = 12) endorsed both statements as representative of their patient 
physician relationship (n = 9), or endorsed one and were unsure about 
the other (n = 3). This is evidence for the fact that the relationship 
between patient and physician is a complex one. It is possible that the 
physician’s manner is participatory at some points and directive at other 
points -- making the general nature of his/her practice difficult to 
determine. 
Diary Versus Non-Diary 
T-tests were conducted to determine whether the group 
completing the medication diary differed from the control group on any of 
the variables. None of these tests yielded significant results (see Table 
5), indicating that notwithstanding the effects of completing the diary, the 
two groups were not different. 
Relationships Among Independent Variables 
Correlations. 
Correlations were calculated between all Independent variables to 
Identify any significant relationships (see Table 6). 
Age did not correlate significantly with any of the variables in 
question. This indicates that knowing a patient’s age will not help one to 
predict with any certainty what her score will be on the other variables. 
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Table 5 
T-tests of Group (Diary vs Non-Diary) by independent Variables. 
Variable T-test 
Age 








internal Health Locus 
of Control 
Chance Health Locus 
of Control 
Powerful Others Health 
Locus of Control 
Desirability of Control 
Profile of Mood States 






t = -1.58, p = .133 
t = .70, p = .499 
t = .76, p = .460 
t = -.56, p = .580 
t = .20, p = .845 
t = -.33, p = .747 
t = .83, p = .420 
t = -.11, p = .915 
t = -.82, p = .422 
t = -.49, p = .634 
t = -.16, p = .873 
t = 3.51, p = .148 
t = 1.85, p = .081 
t = -1.28, p = .218 
t = .25, p = .807 
* = the non-diary group all gave a rating of 7 for this 





























































































Patients' prediction of compliance (or anticipated difficulty with the 
regimen) did not correlate significantly with any of the other independent 
variables. Of particular interest, patients' predictions of their compliance 
and oncologists' predictions of patients' compliance did not appear to be 
related (r = .1797, p = .448). 
There was a tentative, although nonsignificant, relationship 
between patients' predictions of compliance and a directive patient- 
physician relationship (r = -.3999, p = .081). The negative correlation 
may appear to suggest that lower predictions of compliance and directive 
relationships are somewhat related but the wording of the difficulty scale 
was such that higher scores would indicate a greater likelihood of non- 
compliance. Thus, these results indicate that there Is a nonsignificant 
tendency for those patients who report a strongly directive patient- 
physician relationship to predict higher levels of compliance. On the 
other hand, patients' predictions of their compliance and participatory 
patient-physician relationships do not appear to be related (r = .0175, 
p = .942). 
Months since first treatment was most strongly correlated with 
oncologists' prediction of compliance (r = -.7098, p < .001). It appears 
that the longer It had been since the patient was first prescribed 
Tamoxifen, the lower the oncologists' prediction of compliance was. This 
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is especially interesting since patients' predictions of their own 
compliance were not significantly related to months since first treatment 
(r = -.3463, p = .135). It would seem that oncologists may be basing 
their estimation of patients' likely compliance rate on a factor that patients 
themselves do not feel is important. 
There was a significant correlation between Internal Health Locus 
of Control , (IHLC) and months since first treatment (r = .4969, p < .05). 
Those subjects who reported an internal locus of control also tended to 
have been on Tamoxifen for a longer period of time. Perhaps having the 
opportunity to become more involved in one's treatment by taking 
Tamoxifen increases the belief one has in one's own control over health 
matters. Or perhaps those patients high In IHLC are more likely to stay 
on the regimen for an extended period of time. 
Given the significant positive correlation between IHLC and 
months since first treatment, a negative correlation might be expected 
between months since first treatment and the other locus of control 
scales (Chance and Powerful Others) which tap into external locus of 
control. These correlations are negative but the relationships do not 
reach statistical significance (r = -.3262, p = .160 [Chance] and 
r = -.2874, p = .219 [Powerful Others]). 
Chance Health Locus of Control (CHLC) correlated significantly 
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with ECOG rating (r = -.6761, p < .01) indicating that those who attribute 
control in health matters to chance factors tend to show higher levels of 
physical functioning. This is an interesting result which Is somewhat 
puzzling at first glance. However, the source of the relationship will 
become more clear when the results of the t-tests for present status are 
presented. 
The CHLC and PHLC scales were significantly correlated 
(r = .4751, p < .05) as would be expected since they both represent 
measures of external locus of control. 
As has already been noted, a negative correlation would be 
expected between the participatory and directive relationship questions to 
confirm that these questions are evaluating distinct contrasting styles of 
Interacting. Although a negative correlation is found between these two 
questions, the relationship does not reach statistical significance (r = - 
.3232, p = .165). Perhaps with more questions to evaluate the patient- 
physician relationship and more subjects, a clearer result will be found. 
There was a tentative, though not statistically significant 
relationship between ECOG rating and directive patient-physician 
relationships (r = .3975, p = .083).. There does not appear to be any 
relationship between ECOG rating and participatory relationships (r = - 
.0302, p == .900). 
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Patients reporting a higher quality of life on the FLIC tended to 
report a participatory relationship with physicians (r = .6135, p < .01). 
This is a fascinating finding. It may be that patients whose quality of life 
is high and who are not actively ill are more likely to take an active part in 
their relationship with their oncologist. It may also be that physicians feel 
more comfortable acting in a participatory manner with patients whose 
quality of life is high. On the other hand, those who had a directive 
relationship with physicians did not report a significantly lower quality of 
life, though there was a nonsignificant tendency in that direction (r = - 
.4028, p = .078). This (FLIC and participatory) was the only statistically 
significant correlation involving either the participatory or the directive 
variables. As has already been mentioned, some relationships do 
approach significance. Therefore, rather than concluding that patient- 
physician interaction is not related to these variables, it is suggested that 
better measures of the interaction be developed so that more information 
can be gleaned. 
Neither the Profile of Mood States nor the Desirability of Control 
Scale correlated significantly with any of the other independent variables 
(see Table 6). In terms of Desirability of Control, the strongest 
suggestion of a relationship involves that measure and quality of life (r = 
.3829, p = .096). 
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Neither the Patients' Impressions Scale nor the Patients' 
Satisfaction Visual Analog Scale correlated significantly with any of the 
other variables. Scores on both these variables were very high, with little 
variance. In addition to the fact that highly satisfied patients with 
favourable impressions of the Cancer Centre might be more likely to 
participate in a study such as this, patients may not have been 
comfortable expressing even slightly negative opinions. Perhaps more 
work could be done to develop more subtle Items. 
T-Tests of Present Status. 
T-tests were conducted to determine whether disease-free patients 
differed from patients with a recurrence or metastatic disease on any of 
the variables (see Table 7). 
The t-test of present status by age yielded significant results 
(t = 3.27, p < .05). This indicates that two present status groups 
significantly differed on this variable. 
These two groups also differed on CHLC (t = 2.15, p < .05). 
Given that we know that CHLC was significantly correlated with ECOG 
rating, we can infer that those patients who are free of disease and are 
thus likely to be high on physical functioning, tend to attribute control in 
health matters to chance factors. 
Finally, the t-test comparing the present status groups on 
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Table 7 
T“tests of Present Status (Disease-free vs Recurrence/Metastatic 
Disease) by Independent Variables. 
Variable T-Test 
Age 







Internal Health Locus 
of Control 
Chance Health Locus 
of Control 
Powerful Others Health 
Locus of Control 
Desirability of Control 
Profile of Mood States 





Patients' Satisfaction * 
t = 3.27, p < .05 * 
t = -1.67, p = .112 
I 
t = 2.02, p = .059 
t = -1.02, p = .387 
t = 2.15, p < .05 * 
t = .76, p = .519 
t = .32, p = .777 
t = .98, p = .342 
t =:= .18, p = .864 
t = .11, p = .922 
I 
t = -.95, p = .412 
! 
* = statistically significant 
! = All members of the recurrence/metastatic group gave the 
same rating on these variables. Since there was no variance for this 
group, a t-test could not be performed. 
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oncologist compliance ratings revealed a difference that approaches 
significance (t = 2.02, p = .059). Perhaps with a larger sample, 
especially a larger group of recurrence/metastatic patients, the results 
would be more definitive. 
Pill Count Relationships 
The mean pill count for the non-diary group was 90.0 
(sd = 22.853, n = 9), while for the diary group it was 85.636 
(sd = 21.906, n = 11). It is important to note that the two groups are 
unequal in size. This is because the two subjects whose data had to be 
excluded because of not bringing the medication to the meetings were 
both originally assigned to the non-diary group. A t-test conducted on 
these groups revealed that the means are not significantly different 
(t = .43, p = .671). 
In spite of this non-significant result, the data was examined more 
closely. In particular, two interesting observations were examined. First, 
six of the observations making up the data indicated that more than 
150% of the medication was ingested (i.e. if according to the 
prescription it was expected that the patient would take 10 tablets, at 
least 15 would be "missing" at the next meeting). This could have had 
the effect of distorting one or both of the means. However, the six 
observations were equally distributed among the two groups, eliminating 
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this as the cause of a difference between the groups. 
Secondly, subjects sometimes forgot to bring the medication to 
the meetings with the investigator. It appeared that this phenomenon 
occurred more often among subjects in the non-diary group than among 
those in the diary group. A chi-square test revealed however that this 
did not happen significantly more often In the non-diary group (= 
1.014, p > .05). Interestingly, when data for the two subjects who did 
not bring the pills to any of the meetings with the investigator were 
entered into the equation, the chi-square was significant and the non- 
diary group then appeared to be less compliant in bringing medication to 
the meetings (= 6.471, p < .02). 
After investigation of the possible effects of group, correlations 
were calculated between the average pill count and all other independent 
measures to identify any significant relationships (see Table 8). 
Only one correlation proved to be statistically significant. This was 
between compliance and age (r = .5042, p < .05). Older women tended 
to be more compliant than younger women. This may be related to 
socialization issues - perhaps older women were taught more than their 
younger counterparts to view physicians as powerful and all-knowing. Or 
it may be that older women see themselves as more vulnerable and thus 
are more likely to comply with physician's recommendations. 
Table 8 










Internal Health Locus 
of Control 
Chance Health Locus 
of Control 
Powerful Others Health 





Functional Living Index - 
Cancer (FLIC) 
Desirability of Control 
Profile of Mood States 
ECOG Rating 
r = .5042, p < .05 * 
r = .1956, p = .409 
r = -.0022, p = .993 
r = .0576, p = .809 
r = -.1394, p = .558 
r = -.0350, p = .884 
r = -.2009, p = .396 
r = .1557, p = .512 
r = -.1733, p = .465 
r = -.0358, p = .881 
r = -.1280, p = .591 
r = .1878, p = .428 
r = .2751, p = .240 
r = .0016, p = .995 
r = -.3652, p = .113 
* = statistically significant 
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Patients' prediction of compliance and pill count yielded a 
correlation of -.0022, p = .993. It appears that the degree to which one 
expects to comply with the regimen and actual compliance are not 
related. 
Oncologists' prediction of compliance was also not significantly 
related to actual pill count (r = .0576, p = .809). In other words, the 
degree to which the patient follows the medication regimen and the 
degree to which the physician expects the patient will follow the regimen 
are not necessarily the same. 
Compliance was not significantly related to either participatory or 
directive patient-physician relationships (r = -.0358, p = .881 and 
r = -.1280, p = .591, respectively). This may be due to the questions 
used to measure these relationship variables. A more comprehensive 
measure of patient-physician relationship may reveal more about the 
impact of this important interaction on compliance. 
Compliance was also not significantly related to scores on the 
Patients' Impressions Scale or the Patients' Satisfaction Scale 
(r = .1557, p = .512 and r = -.1733, p = .465, respectively). Again 
however, scores on these variables were very high with little variance. 
Better scales and a larger sample size may yield clearer results. 
Finally, compliance was not found to be related to any of the other 
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variables of POMS, IHLC, CHLC, PHLC, or FLIC (see Table 8). 
Regression Analyses 
When all the variables (pill count, age, group, patient compliance 
prediction, oncologist compliance prediction, months since first 
treatment, IHLC, CHLC, PHLC, patients' impressions, patients' 
satisfaction, directive relationship, participatory relationship, FLIC, DC, 
POMS, present status and ECOG rating) were entered for a stepwise 
multiple regression analysis with pill count as the dependent variable, age 
was the only variable entered into the equation (F (1,18) = 6.13, 
p < .05), explaining 25.42% of the variance. This indicates that patient's 
age was the single best predictor of compliance in our study (see 
Appendix N). 
Another stepwise multiple regression analysis (with the same 
variables entered as above) was performed to determine what variables, 
if any, predicted oncologists' compliance prediction. Months since first 
treatment emerged as the single best predictor of oncologists' 
compliance prediction, explaining 50.38% of the variance [F(1,180) = 
18.28, p < .001] (see Appendix O). 
Locus of Control. Desirability of Control and Relationship 
It was hypothesized that locus of control, desirability of control and 
patient-physician relationship would Interact and affect compliance. This 
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hypothesis could not be evaluated however because of the small cell size 
(see Table 9). For example, only one subject reported an internal locus 
of control, a high desire for control and a participatory patient-physician 
relationship. Similarly, only 1 subject reported an internal locus of 
control, a high desire for control and a directive patient-physician 
relationship. A further study using p larger sample size may be better 
able to answer the question of the effect of this interaction on 
compliance. 
Table 9 
Cell Size for Interaction of Locus of Control. Desirability of Control and 
Patient-Physician Relationship 
Participatory Directive 
Low DC High DC Low DC High DC 
IHLC 0 1 ‘ 0 1 
CHLC 0 0 0 0 
PHLC 3 2 10 
Compliance to Study 
In general, subjects were highly compliant in completing the 
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experimental tasks assigned to them. Considering both the pill count 
observations and the questionnaire data, there was a total of 4980 data 
points (249 for each subject). Out of this entire pool, 4956 scores 
orobservations (99.5%) were collected. For the pill count data alone, 65 
out of a possible 80 observations were collected (81.25%). 
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Discussion 
Compliance to medication regimens could very well be the factor 
which turns the tide away from illness and toward health for many 
individuals. With our increasing medical knowledge and the fact that 
cancer is now considered a chronic illness and not necessarily a "death 
sentence", this is as true In the care of cancer patients as it is in other 
types of illness. In addition, compliance can reduce the need for more 
extensive treatment and thus can save health care dollars. 
This study assessed one aspect of the issue of compliance in 
breast cancer patients. It provided some interesting results, and though 
the small sample size renders the results tentative, it has some 
implications for future research in this area. 
Diary versus Non-Diary 
The findings of this study did not support the hypothesis of 
increased compliance in those patients who kept a medication diary over 
those without such a diary. However, it is Important to note that those 
patients in the non-diary group forgot' to bring the medication to the 
meetings with the investigator significantly more often than did those In 
the diary group. In fact, the data from two members of the non-diary 
group had to be excluded from analysis because these subjects failed to 
bring the medication to any of the meetings. Thus, although rate of 
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compliance according to pill count did not significantly differ across the 
groups, subjects completing the di^ry appeared to be more compliant in 
bringing the medication to the meetings. 
The medication diary then may have helped to remind subjects 
that they had been asked to bring the medication to the meetings (a new 
request that one might say had been temporarily added to the regimen), 
though it may not have helped subjects to remember to take their 
medication on a daily basis. Perhaps the diary would have been 
beneficial when the patient was first beginning the regimen to help her to 
incorporate it Into her everyday life. Further, the regimen In this case is 
quite simple - it requires only that the patient take one pill once a day. 
Perhaps a diary would be more helpful In more complex regimens. 
The medication diary also may have inadvertently informed 
patients as to the purpose of the study. If so, subjects may have been 
more careful to comply with the investigator's requests because they 
believed that this was being monitored. It would be Interesting to 
conduct a study in which the subjects were told the true purpose and 
that their pills would be counted. This would provide dearer evidence of 
the impact of such knowledge and would remove this variable from 
potentially confounding the differences between the Diary and Non-diary 
groups. Perhaps we would find that In this case, patients are able to get 
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past self-presentation needs and that concealing the purpose of the 
study is unnecessary. It is also possible that we would find exactly the 
opposite. This would still provide important knowledge for it would lend 
empirical support to a difficult ethical decision. 
It may also be that the subjects in the sample do not benefit from 
the medication diary because they are, as a group, more compliant than 
the general population. Compliance in this case refers to accepting and 
following the advice of a physician. Perhaps those patients who are 
more likely to agree to follow a medication regimen are also more likely 
to agree to participate in a study such as this. 
Further, someone having trouble with the medication regimen 
might not be likely to participate in a study such as this because she 
may feel that she has enough to deal with in coping with and adapting to 
the regimen. She may also not want her problems with the regimen 
brought to light for fear she will be judged negatively. Unfortunately, it is 
one of the inherent difficulties in research such as this that those who 
agree to participate may not be those who could benefit most from the 
study. 
In addition, the lack of a significant difference between the groups 
may be at least partly attributable to the measure of compliance which 
was used. Pill counting has its own limitations, one of which is that 
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though the pills may not be in the bottle you see before you, that does 
not necessarily mean the patient has ingested them. On six occasions 
(out of 60 possible post-baseline observations), the pill count Indicated 
that more than 150% of the medication was ingested. At one point it 
appeared that a patient had consumed three times the prescribed 
dosage. Though this may have been the case, the missing medication 
may also have been transferred to another bottle. Still, these extremely 
noncompliant counts could have masked a true difference between the 
groups. 
Finally, the lack of a significant difference between the groups may 
be due to the small sample size. Perhaps studying more people would 
bring differences to light. 
Patients' and Oncologists' Predictions of Compliance 
It was hypothesized that patients' predictions about their rate of 
compliance would accurately reflect their actual compliance while 
oncologists' predictions would not be as accurate. 
This hypothesis was only partly supported. As expected, it was 
found that oncologists' predictions of compliance did not predict the 
actual compliance which was exhibited. Many studies have 
demonstrated that physicians overestimate the degree of compliance 
exhibited by patients (e.g. Roth & Caron, 1978). In this case however it 
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seems that oncologists' predictions of compliance slightly underestimate 
actual compliance. Perhaps knowledge of the extent of noncompliance 
has prompted physicians to be more conservative in their estimates. 
Further, it may be that the intense relationship between an oncologist 
and his/her patient has allowed the patient and physician to develop a 
deeper relationship than is likely between a patient and a general 
practitioner. Though oncologists are admittedly not accurate In their 
estimations of patient compliance, the particular relationship which can 
develop between a patient and an oncologist might have reduced the 
likelihood of the oncologists' overestimating compliance 
Contrary to the hypothesis, patients' predictions of compliance are 
not related to actual pill count. It Is possible that we did not ask the 
correct question; that In our efforts to assess anticipation of compliance 
without 'suggesting' the 'correct' answer to the patient, we presented a 
rather vague question. Subjects may have interpreted the question 
differently than intended. Perhaps rather than looking to the future and 
anticipating problems which may arise, they looked to the past and 
evaluated what problems they may have had following previous 
treatments. If this is what happened, it would not be surprising that 
patients' ratings were not related to compliance. In addition to the 
possibility of forgetting past incidents of noncompliance, Sheiner et al. 
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(1974) reported that patients commenting on past behaviour may not 
admit to noncompliance because they do not wish to portray themselves 
negatively. 
More work needs to be done to discover an appropriate way of 
assessing the anticipation of patients' own degree of compliance. It may 
be that the ratings would be more accurate and successful if the 
investigator is completely open and let patients know that it is future 
compliance the investigator is concerned with. Otherwise the investigator 
is faced with the difficult task of developing a question whose answer 
predicts compliance without influencing the response by telling the 
subject directly that we are interested in how closely they adhere to the 
regimen. 
Duration of Treatment 
It has been found that compliance decreases as duration of 
treatment Increases (Berger et al., 1988). This does not appear to be so 
in this study. Those who have been on the medication for an extended 
period of time are just as likely to comply as those who have just begun 
Tamoxifen therapy. 
Again the complexity of the regimen may be a factor here. Taking 
one tablet once a day is an easy task to fit into one's schedule. Perhaps 
if the task was more complicated or difficult to perform, or was time 
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consuming, compliance would wane over time. Further, the regimen in 
this case does not require long term lifestyle changes. It is known that 
adherence to recommended lifestyle changes (e.g. dietary regimens) is 
low (Sackett & Snow, 1979; Dunbar & Stunkard, 1979). If the regimen of 
interest required such a change in lifestyle, perhaps a decline in 
compliance over time would be more likely. 
Profile of Mood States 
It was hypothesized that those patients showing signs of mood 
disturbance (as assessed by the POMS) would be less compliant to the 
medication regimen. This hypothesis was not supported, but the reason 
for this is evident. The sample as a whole reported very little mood 
disturbance. In fact, the sample reported significantly less mood 
disturbance than the normative sample of cancer patients. If mood 
disturbance was evident, it may alter compliance but since It does not 
appear to be a factor for this group of subjects, it can hardly be 
expected to affect their compliance. 
Perception of and Satisfaction with the Cancer Centre 
Patients who feel disappointed or dissatisfied when leaving a clinic 
have been found to be less likely to follow advice or take prescriptions as 
required (Bradshaw & Ley, 1975). In light of this, it was expected that 
those subjects reporting positive Impressions of the Cancer Centre 
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and/or reporting overall satisfaction with the Centre would be compliant. 
This hypothesis was not supported by the results. As has already been 
discussed however, scores on these variables were quite high with little 
variance. Better measures of these variables need to be developed 
before conclusions can be drawn. 
Quality of Life 
It was expected that patients reporting a higher quality of life (and 
thus fewer illness symptoms) would be more likely to forget to take their 
medication or to feel that it is not necessary to strictly adhere to the 
regimen. Further, it was hypothesized that as quality of life fluctuated 
over the course of the study, so too would compliance fluctuate. 
Contrary to these hypotheses, score on the FLIC did not predict 
the compliance of these women. However, scores were generally quite 
high, with a mean of 133.363. This indicates that as a group, these 
women felt that the quality of their lives was quite good. Since this 
sample did not include people who felt the quality of their lives was low, 
we can not expect to find differences based on low versus high quality of 
life. 
Further, scores on the FLIC remained consistently high over the 
course of the study. Obviously, the lack of change in quality of life 
removes the possibility of a change in compliance based on a fluctuation 
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in FLIC score. 
Several subjects commented that they felt some of the questions 
on the FLIC did not apply to them since it had been some time since 
their original diagnosis and treatment (e.g. questions concerning 
nausea). Perhaps for those women who have just been diagnosed, 
compliance would be more closely linked with quality of life measured by 
the FLIC. That certain questions were not applicable to this sample also 
emphasizes the importance of designing quality of life measures for 
different times across the lifespan of an illness. 
Locus of Control. Desirability of Control and Relationship 
People who reported an internal locus of control and who had a 
high desire for control were expected to be more compliant if their 
relationships with their oncologists allowed for this internal/high desire 
control, than similar patients whose relationships with their oncologists 
did not allow for such control. Similarly, patients reporting an external 
locus of control and little desire for control were expected to be more 
compliant if their relationships with their oncologists were directive, than 
similar patients whose relationships with their oncologists allowed 
patients considerable control. 
Unfortunately, there were insufficient numbers of subjects in this 
study to adequately evaluate this complicated hypothesis. However, 
74 
some comments can be made on the individual components of the 
hypothesis. 
Locus of Control 
None of the three scales of locus of control (Internal, chance and 
powerful others) were significantly related to compliance. However, this 
should not necessarily be taken to mean that such a link does not exist. 
Most patients in this sample attributed control in health matters to 
Powerful Others. 
Mahon, Sellick and Sellick (1991) reported similar results. Several 
of their subjects reported a Powerful Others Health Locus of Control. 
Further, they found that in anticipation of Cancer Centre follow-up 
appointments, those patients who believed powerful others controlled 
their health experienced lower levels of stress and dreaded the visit less 
than those attributing control to other factors. Considering that the 
physician may be the "Powerful Other", thinking this way could lead to 
reduced stress and dread because the visit would mean being monitored 
by the person who has the power and the ability to make and keep them 
well. It may be that those patients who have been or are seriously ill are 
more likely to attribute control to a "Powerful Other". A study conducted 
with a larger sample size may yield sufficient numbers for each type of 
locus of control to Illustrate what, if any, effect this variable has. 
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Desirability of Control 
Since following a prescribed medication regimen can be 
interpreted as a way the individual can take some control over her health, 
it would have been expected that increased desirability of control would 
lead to increased compliance. This hypothesis was only tentatively 
supported. However, desirability of control for these subjects was 
generally low and the mean was significantly lower than the normative 
mean. The low desirability of control demonstrated in this study is 
consisted with the results of Mahon, Sellick and Sellick (1991) who found 
low desirability of control in a sample of cancer patients with a mean age 
of 60.6 years. It is known that desirability of control decreases with age 
(Sarafino, 1990) and so a lower desirability of control in the present 
sample whose mean age is 60.3 years compared to a sample of college 
students (Burger & Cooper, 1979) is not remarkable. Perhaps younger 
subjects' compliance would show a greater variance according to 
desirability of control. 
Patient-Physician Relationship 
The questions asked in this study to determine the nature of the 
patient-physician relationship did not seem to adequately discriminate 
whether the relationship was generally participatory or directive. This 
provides evidence for the fact that the relationship between patient and 
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physician is a complex one. It is possible that the physician's manner is 
participatory sometimes and directive at other times -- making the 
general nature of his/her practice difficult to determine. The nature of 
his/her practice may vary in accordance with what the physician discerns 
to be what the patient is in need of (e.g. given the stage of the illness or 
the patient's emotional state) as much as it varies in accordance to what 
the physician needs to offer. 
More work needs to be done to develop a scale which adequately 
evaluates the intricacies of the patient-physician relationship. 
Limitations and Suggestions for Future Research 
While the greatest limitation of this study may be its small sample 
size, the results do provide us with some clearer ideas on what questions 
to ask in an extension of this research. 
Although no specific hypothesis was formulated in regard to 
patients' age, It was found that patients' age was significantly related to 
compliance in that older women were more compliant than younger 
women. This may be a very important finding and may provide 
indications for clinical application. It may be that older women perceive 
themselves as more vulnerable to a recurrence and thus are more likely 
to comply with the regimen. Conversely, younger women may perceive 
themselves as less vulnerable either because of the feeling of Invincibility 
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which often accompanies youth or because to take the drug would be to 
admit the possibility of further illness and perhaps death. This reality may 
be so painful to deal with that young women cope by denying its 
existence and not complying with the medication regimen. In either 
case, these results should be further investigated to find out the true 
nature of the difference. In the meantime, physicians should be 
encouraged to pay special attention to the needs of younger patients as 
a group who is at risk of noncompliance. Spending some extra time with 
these patients and educating them as to the specifics of their disease 
may be able to reduce their need for denial as a coping mechanism. 
Suggestions for clinical application can also be gleaned from the 
results in that oncologists' tended to base their predictions about 
patients' compliance rates on the length of time which had passed since 
the patient first began Tamoxifen therapy. Not only are oncologists' 
predictions not reflective of actual compliance rates - duration of 
treatment is also not related to compliance rates. If oncologists were 
provided with this information, they may be able to change the 
assumptions they make about patient compliance and then may be able 
to judge the likely rate of adherence more accurately. 
A significant relationship was found between quality of life and 
participatory patient-physician relationships in that patients who were 
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experiencing fewer illness symptoms tended to report having a 
participatory relationship with their oncologist. It may be that patients 
whose quality of life is high demand a more active part in the 
relationship, or that physicians feel more relaxed and more comfortable 
acting In a participatory manner with patients who are not actively ill, or a 
combination of these effects. More research needs to be conducted to 
expand upon these results and to discover the explanation for this 
relationship. 
Also, better questions need to be developed which evaluate the 
nature of the patient-physician relationship. Using interviews may be one 
way of evaluating the relationship - both patient and physician could be 
approached to provide data on their interaction with each other. Only 
with a better way of determining the nature of the patient-physician 
interaction can we find out how the relationship affects compliance and 
how to best achieve a "match" between patient and physician that will 
maximize compliance. 
It is possible that the present status of the subjects influenced the 
data and contributed to the negative results which were found. Eighty- 
five percent of the sample was disease-free, leaving only 15% who were 
actively waging a battle with cancer while data collection was taking 
place. It may be that patients who are experiencing a recurrence or 
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metastatic disease are less likely to comply with the regimen because 
they became ill again even after taking the drug. They may feel they 
have been let down by the medical advice and doubt its utility. 
Comparing larger equivalently sized group of disease-free and 
recurrence/metastatic disease patients would provide more information 
on the impact of this variable. 
A question needs to be developed which will clearly ask for a 
prediction of future compliance. Directly asking the patients is one 
solution. Otherwise it would need to be worded so that it does not 
influence the answer by suggesting the "appropriate" response. This 
may sound like a simple task but to many people even suggesting 
problems or memory difficulties can bring on defensiveness. Thus, the 
question must be accepting of human frailties as well as neutral. 
It would be interesting to study two distinctive groups - one which 
has just been diagnosed and one that was diagnosed some time ago. 
This would allow us to better evaluate the effects of duration of treatment 
and the effects of quality of life and its fluctuations on compliance. A 
further investigation might also compare anticipated compliance among 
newly diagnosed patients and healthy people. Dr L Degner working with 
the World Health Organization (1991) has been studying a similar Issue 
and reports that patients generally do not behave as they had anticipated 
80 
they would. 
The influence of locus of control and desirability of control on 
compliance should be further explored to determine whether these 
variables Interact to affect compliance. 
Finally, in the future the use of pill count as a measure of 
compliance should be supplemented with biological measures such as 
blood or urine analysis. This was not possible in this study because of 
lack of funding and the limitations of the local facilities and equipment. 
Though neither of these methods is without Its problems, if they were 
used together one could have more confidence that the measure one Is 
getting is accurate. 
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Appendix A 





This is a questionnaire designed to determine the way in -which t 
different people view certain important health—related issues, | 
Each item is a belief statement with which you may agree or f 
disagree. Each statement can be rated on a scale which ranges \ 
from strongly disagree (1) to strongly agree (6). For each item 1 
we would like you to record the number that represents the extent \ 
to which you disagree or agree with the statement. The more | 
strongly you agree with a statement, then the higher will be the i 
number- you record. The more strongly you disagree with a | 
statement, then the lower the number you record. Please make | 
sure that you answer every item and that you record only one I 
number per item. This is a measure of your personal beliefsj | 
obviously, there are no right or wrong answers. | 
Please answer these items carefully, but do not spend too much | 
time on any one item. As much as you can, try to respond to each I 
item independently. When making your choice, do not be | 
influenced by your^ previous choices- It is important that you ^ 
respond according to your actual beliefs and not according to how | 




1 Strong Iy disagree 
2 ~ Hoderately disagrGG 
3 - Slightly disagreo 
4 - Slightly agree 
5 - Hodorately agrcG 
6 - Strongly agree 
1. If I get sick, it is my own behaviour which determines 
how soon I get well again. 
2. No matter what I do, if I am going to get sick, I will 
get sick- 
3. Having regular contact with my physician is the best way 
for me to avoid illness. 
4. Most things that affect my health happen . to me by 
accident, 
5. Whenever I don^t feel well, I should consult a medically 
trained professional. 
6. I am in control of my health- 
7. My family has a lot to do with my becoming sick or 
staying healthy- 
8. When I get sick, I am to blame. 
9. Luck, plays a big part in determining how soon I will 
recover from ah illness. 
10. Health professionals control my health- 
11. My good health is largely a matter of good fortune. 
12. The main.thing which affects my health is what I myself 
do. ^ 
13. If I take care of myself, I can avoid illness. 
*^14. When I recover form an illness, it's usually because 
other people Cfor example, doctors, nurses, family, 
friends) have been taking care of me. 
15. No matter what I do, I'm likely to get sick. 
16. If it's meant to be, I will stay healthy- 
, 17. If I take the right actions, I can stay healthy. 
18. Regarding my health, I can only do what my doctor tells 
me to do- 
2 
Appendix B 
Desirability of Control Scale 
BELOW YOU WILL FIND A SERIES OF STATEMENTS. 
PLEASE READ EACH STATEMENT CAREFULLY AND RESPOND TO IT BY 
EXPRESSING THE EXTENT TO WHICH YOU BELIEVE THE STATEMENT 
APPLIES TO YOU. 
FOR ALL ITEMS A RESPONSE FROM 1 TO 7 IS REQUIRED. 
CIRCLE THE NUMBER THAT BEST REFLECTS YOUR BELIEF WHEN THE 
SCALE IS DEFINED AS FOLLOWS; 
1 = The statement doesn't apply to me at all. 
2 = The statement usually doesn't apply to me. 
3 = Most often, the statement does not apply. 
4 = 1 am unsure about whether or not the statement applies to me, 
or it applies to me about half the time, 
5 = The statement applies more often than not. i 
6 = The statement usually applies to me. j 
7 = The statenient always applies to me. i 
I prefer a job where I have a lot of control over 
what I do and when I do it. 
2 3 4 5 6 7 
I enjoy political panicipation because I want to have 
as much of a say in running government as possible. 
1 2 3 4. 5 6 7 
I try to avoid situations where someone else tells me  1 2 3 4 
what to dp. 
5 6 7 
I would prefer to be a leader rather than a follower.  12 3 4 
I enjoy being able to influence the actions of others  12 3 4 
$ 
I am careful to check everything on an automobile   1 2 3 4 
before t leave for a long trip. 
Others usually know what is best for me.   12 3 4 
enjoy making my own decisions.   12 3 4 
enjoy‘having control over my own destiny.   12 3 4 
would rather someone else take over the leadership  12 3 4 
>le when I'm involved in a group project. 
5 6 7 
5 6 7 
5 6 7 
5 6 "T 
5 6 7 
5 6 7 
5 6 7 
I consider myself to be generally more capable of 
handling situations than others are. 
['d rather run my own business and make my own 
mistakes than listen to someone else's orders. 
I like to get a good idea of what a job is all about 
before I begin. 
When I see a problem, I prefer to do something 
about it rather than sit by and let it continue. 
When it comes to orders, I would rather give them 
than receive them. 
I wish I could push many of life's daily decisions off 
on someone else. 
Wheri driving, I try to avoid putting myself in a 
situation where I could be hurt by someone else's 
mistake. 
I prefer to avoid situations where someone else has 
to tell me what it is I should be doing. 
There are many situations in which I would prefer 
only one choice rather than having to make a 
decision. 
I like to wait and see if someone else is going to 
solve a problem so that I don't have to be bothered 
with it. 
Appendix C 





OUR OVERALL ENJOYMENT OF LIFE n 
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Functional Living Index - Cancer 
PLEASE TAKE A PEW MINUTES AND RESPOND TO EACH OF THE FOLLOWING 
QUESTIONS. THERE ARE NO RIGHT OR WRONG ANSWERS. SIMPLY CIRCLE 
THE NUMBER (1 - 7) THAT MOST ACCURATELY REFLECTS■ YOUR SITUATION.- 
1, Most people experience some feelings of depression at 
times. How often to you have these feelings? 
1 2 3 4 5 6 -7 
never continually 
2. How well are you coping with your everyday stress? 
1 2 3 4 5 6 7 
well not well 
3, How much time do you spend thinking about your illness? 
1 2 3 4 5 ‘6 7 
constantly ‘ never 
Rate your ability to maintain your usual recreation or 
leisure activities. 
1 2 3 4 5 6 7. 
able unable 
5, Has nausea affected your daily functioning? 
1 2 3 4 5 6 7 
not at all a great deal 
5. How well do you feel today? 
L 
L 2 3 4 5 6 7 
‘.xtremely poor extremely well 
Do you feel well enough to make -a meal or. do minor 










3 4 5 6 7 
not able 
degree to which you cancer has imposed a hardship 
closest to you in the past two weeks. 
3 4 5 6 7 
tremendous ‘hiardship 
often you feel discouraged about your life. 
3 4 5 6 7 
10 . Rate your satisfaction with your work and your jobs 
around the house in the past month. 
12 3 
very dissatisfied 
4 5 6 7 
very satisfied 
11. How uncomfortable do you feel today 
1 2 3 4 5 6.7 
not at all very uncomfortable 
12. Rate, in your opinion, how disruptive your cancer has been 
to those closest to you in the past two weeks, 
1 2 3 4 5 6 7 
totally disruptive no disruption 
13 . How much is pain or discomfort interfering with your 
daily life? 
1 2 3 4 5 6-7 
not at all a great deal 
l±. Rate the degree to which your cancer has imposed a hardship 
on you, personally, in the past two weeks. 
2 3 4 5 6 7 
remendous hardship no hardship 
_5. How much of your usual household tasks are you able 
to complete? 
2 3 4 5 6 7 
11 none 
1 
[, Rate how willing 
those closest to 
2 3 
willing 
you were to see and 
you in the past two 
4 5 




. How much nausea have you had in the past two weeks? 
le 
6 7 
a great deal 
2 3 4 5 
^ ® 7 
Kate ho.„ . "°t afraid 
constantly terrified 
-'Ot w wiJi-iy^ 
friends in i-hf^ i'ou were to == in the past t o ®nd 
^eeks. 
4 
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People often report difficulty taking their medication (e.g. 
forgetting to take their pills). Using the following scale, 
please rate the degree to which you think that you may 
have difficulty taking (remembering to take) your 
medication. 
0 = no problems 
1 =few problems 
2 =some problems 
4 = many problems 
Appendix F 
Patients' Impressions of TBRCC Scale 
PATIENTS IMPRESSIONS OF THE 
THUNDER BAY REGIONAL CANCER CENTRE 
Please read the following statements carefully. This is not a test, for your 
responses merely reflect your opinions and experiences. All responses will remain 
strictly confidential. 
Please note that some of the statements are worded positively and some are 
deliberately worded negatively so that you may express your opinions accurately. 
Use the following scale when indicating the degree to which you agree with each 
statement Please place the appropriate number on the line found next to each 
statement 
—3 ""2 “”1 0 +1 +2 +3 
Strongly moderately mildly neither agree mildly moderately strongly 
disagree disagree disagree nor disagree agree agree agree 
PART A: 
1. I was satisfied with the care I received at the Thunder Bay Regional Cancer 
Centre (TBRCC). 
2. In general, during my visits at the TBRCC, the amount of time I spent 
waiting was unreasonable (i.e. waited too long for treatment, check-ups, 
blood-work, etc.). 
3. ! would recommend to others that they make use of the services 
available at the Thunder Bay Regional Cancer Centre. 
4. In general, I was not pleased with my contact with the staff at the 
Thunder Bay Regional Cancer Centre. 
PART B: 
-3 -2 -1 0 +1 +2 +3 
Strongly moderately mildly neither agree mildly moderately strongly 
disagree disagree disagree nor disagree agree agree agree 
1. I am satisfied with the relationship I had with the physicians. 
2. The physicians encouraged me to participate in the 
decision about what treatment would be best for me. 
3. I am satisfied with the relationship I had with the nurses. 
4. The physicians were not able to answer my questions to my 
satisfaction. 
5. In my dealings with the nurses I felt free to express myself and ask 
questions. 
6. The physicians decided what treatment would be best for me and expected 
me to follow their advice. 
7. The nurses were not able to answer my questions to my satisfaction. 
8. In my dealings with the physicians I felt free to express myself and ask 
^questions. 
LEASE INDICATE YOUR OVERALL SATISFACTION WITH THE CARE YOU RECEIVED 
extremely  extremely 
dissatisfied satisfied 
(please place a mark along the line that reflects your degree of satisfaction) 
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Appendix G 
Patient Information Sheet 
TO BE COMPLETED BY MEDICAL ONCOLOGIST 




PRESENT STATUS:  
ECOG PERFORMANCE SCORE: 
[ ] [ ] [ ] [ ] [ ] 
0 12 3 4 
RATE YOUR ESTIMATE OF THIS INDIVIDUAL’S COMPLIANCE: 
extremely extremely 
noncompliant compliant 








ECOG RATING SCALE 
0 = Fully active, able to carry out all pre-disease activities without 
restrictions. 
1 = Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature (e.g. light housework, office 
work). 
2 = Ambulatory and capable of all self-care but unable to carry out any 
work activities. Up and about more than 50% of waking hours. 
3 = Capable of only limited self-care - confined to bed or chair more 
than 50% of waking hours. 
4 = Completely disabled. Cannot carry out any self-care and confined to 
bed or chair. 
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Appendix I 
Initial Phone Call Information 
Initial Phone Call Information 
My name is Tena Jackson. I’m a clinical psychology student at 
the Thunder Bay Regional Cancer Centre. I’ve been working with Dr. 
Scott Sellick and some of the physicians at the Centre. I understand that 
you have been a patient at the Centre and I’m calling to ask if you would 
be interested in helping me out with a research project that would involve 
you completing a few questionnaires. 
We are trying to learn more about difficulties patients may have 
with treatment and with coming to the Centre in general so that we can 
identify areas where we can make improvements. 
It will involve a time commitment. 1 will meet with you at Amethyst 
House - directly across from the Centre - four times over a six week 
period. The first meeting will take approximately half an hour and the 
second, third and fourth meetings will take about 15 minutes each. 
Are you at all interested in helping me with this project or do you 
have any questions? 
**For statistical purposes, I will need for you to bring any 
medication that has been prescribed to you to each meeting. 
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Appendix J 
Informed Consent Form 
The Ontario Cancer Treatment and Research Foundation 
La Fondation Ontarienne Pour La Recherche en Cancerologie et Le Traitement du Cancer ^ 
THUNDER BAY REGIONAL CANCER CENTRE Q 
lENTRE REGIONAL DE CANCEROLOGIE DE THUNDER BAY 
290 Munro Street, Thunder Bay, Ontario P7A 7Tl 
INFORMATION AND CONSENT FORM 
FOR PARTICIPANTS IN A STUDY OF 
ATTITUDES. BELIEFS AND BEHAVIOURS 
OF WOMEN WHO HAVE HAD BREAST CANCER 
This is a brief outline of the nature and purpose of the study in which we hope you will 
agree to participate. We are interested in learning more about difficulties that cancer 
patients may have with their ongoing treatment, so that we can identify areas where 
improvement can be made to benefit those people who have had cancer. 
Participants will be asked to complete some questionnaires that will contain questions 
about their beliefs, attitudes and behaviours, and will be asked to meet with the 
investigator every two Weeks, for six weeks. This will take approximately one hour of your 
time for the first meeting, and approximately 15 minutes for each of the second, third and 
fourth meetings. 
Participants will be assigned a number that they are to use when completing the 
questionnaires, and only the researcher will know their identity. Their physician (s) will be 
aware of their participation but will not have access to any of the information given in the 
questionnaires. All responses will remain strictly confidential. 
If you have any questions about the study or about your role, please feel free to contact 
Dr Sellick or myself at any time. We can be reached by calling the Thunder Bay Regional 
Cancer Centre between 8:30 and 4:30, at 343-1680. If you leave a message, we will 
return your call. 
Thank you for your consideration, 
'k'^'ie'k-k'kic-k'ki^'k’k-k-k'ic'k'/c'k'Aic'k'kfrk'k'k'ie'ie'kitikicik'k'k'icik'is'itffk'fciffrieitfcicic-kfcitifk'k'k'fc'k'kicrkicic'icick'ic'k-tsrkieifk-k'k-irkik 
I have read the above and have spoken with the investigator, Mrs. Tena Jackson. I am 
willing to participate in the above mentioned study and understand what will be expected 
of me. 1 have been assured that my participation is voluntary, and that should I not 
choose to participate, I may still make use of the psychological services available at the 






INSTRUCTIONS TO PARTICIPANTS 
In order to learn more about difficulties that cancer patients may have 
with their ongoing treatment, we are asking a number of patients to 
complete some questionnaires. We wish to identify areas where 
improvement can be made for the overall benefit of people who have had 
cancer. In addition, we are asking participants to keep track of all 
medication, prescribed by a physician, that they are presently taking. 
Please bring those medications (and the record sheets) with you when you 
meet with the researcher. A new record sheet will be given to you. 
t. 
SUBJECT NUMBER 
DATE & TIME 
RECORD SHEET 
MEDICATION TAKEN NO. OF TABLETS 
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Appendix L 
Mean Compliance Prediction For Attending Oncologists 
Oncologist # Patients • Mean Standard Deviation 
1 8 6.125 1.126 
2 5 6.2 .447 
3 5 4.8 2.167 
4 2 6.5 .707 
Appendix M 
Paired T-Tests of FLIC Scores 
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p = .396 
t=-1.05 
p = .306 
t = -.45 
p = .660 
t = -.89 
p = .382 
t = -.50 
p = .624 
t = .28 
p = .780 
t=.34 
p = .740 
t=.76 
p = .456 
t=1.01 
p = .323 
t = -.18 
p = .859 
Appendix N 
Multiple Regression for Pill Count 
With All Other Variables 
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R = .2542, F (1,18) = 6.13, p < .05 
Variable Beta 
Age .50417 2.477 < 05 
Appendix O 
Multiple Regression for Oncologist Compliance 
Prediction With All Other Variables 
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R = .5038, F(1.18) = 18.28, p < .001 
Variable Beta t 
Months since -.7098 -4.28 
first treatment 
P 
< .001 
